CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 70 enrolled
Drug / intervention
photobiomodulation +2 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02000908
NCT02000908N/ACompleted
CompareCT.gov

Prospective, Randomized, Double Blind Study of Photobiomodulation Therapy Using the Realief Therapy System for the Treatment of Chemotherapy-associated Peripheral Neuropathy

University of Minnesota·interventional·Posted Dec 4, 2013·Updated Feb 11, 2019

In Brief

A clinical study evaluating photobiomodulation, Sham treatment, and 1 other intervention for Chemotherapy-induced Peripheral Neuropathy. Completed, enrolled 70 participants across 1 site.

Detailed Summary

This is a 2-armed, randomized, sham-controlled, double-blinded clinical trial of photobiomodulation therapy using the Realief Therapy system. The patients will be randomized in a 3:4 ratio to treatment or sham arms.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChemotherapy-induced Peripheral Neuropathy
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedDec 4, 2013
Enrollment StartJan 1, 2014
Primary CompletionJan 7, 2016
Study CompletionJan 6, 2017
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 12.6 years ago

Interventions

photobiomodulationdevice

The photobiomodulation delivered by Realief Therapy involves amplitude wavelength light delivered by a class IV therapeutic laser.

Sham treatmentother

All patients in sham treatment arm cross over to laser therapy followed by physiotherapy

Physiotherapyother

Chiropractic massage and lymphedema treatment